Get the Stockscreener App
0.021
0.00%
0.00
Virpax Pharmaceuticals Inc stock is traded at $0.021, with a volume of 120.
It is up +0.00% in the last 24 hours and up +89.19% over the past month.
See More
Previous Close:
$0.021
Open:
$0.0114
24h Volume:
120
Relative Volume:
0.49
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-13.24M
P/E Ratio:
-0.00238
EPS:
-8.83
Net Cash Flow:
$-16.85M
1W Performance:
+0.00%
1M Performance:
+89.19%
6M Performance:
-97.91%
1Y Performance:
-99.74%
1-Day Range:
$0.0114
$0.0114
1-Week Range:
$0.0114
$0.0114
52-Week Range:
$0.01
$0.2869
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Name
Virpax Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare VRPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.0114 | 0 | 0 | -13.24M | -16.85M | -8.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
418.39 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
490.08 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.10 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
847.29 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.95 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Virpax Pharmaceuticals Inc Stock (VRPX) Latest News
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
Nanotechnology Stocks To Watch Today – September 1st - Defense World
Head-To-Head Comparison: Virpax Pharmaceuticals (NASDAQ:VRPX) vs. Evotec (OTCMKTS:EVTCY) - Defense World
Virpax reports positive study results for pain management drug - MSN
Top Nanotechnology Stocks To Follow Today – August 25th - Defense World
Promising Nanotechnology Stocks To Watch Now – July 16th - Defense World
Promising Nanotechnology Stocks To Watch NowJuly 16th - MarketBeat
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Down 2.9% – Should You Sell? - Defense World
Promising Nanotechnology Stocks To Add to Your Watchlist – July 9th - Defense World
Top Nanotechnology Stocks To Follow NowJuly 10th - MarketBeat
Promising Nanotechnology Stocks To Add to Your WatchlistJuly 9th - MarketBeat
Nanotechnology Stocks To Watch Today – July 7th - Defense World
Nanotechnology Stocks To Research – July 3rd - Defense World
Best Nanotechnology Stocks To Add to Your WatchlistJune 16th - MarketBeat
Top Nanotechnology Stocks Worth WatchingJune 17th - MarketBeat
Best Nanotechnology Stocks To Keep An Eye OnJune 15th - MarketBeat
Nanotechnology Stocks To Watch NowJune 14th - MarketBeat
Promising Nanotechnology Stocks To ResearchJune 11th - MarketBeat
Nanotechnology Stocks To ResearchJune 8th - MarketBeat
Nanotechnology Stocks To Follow NowJune 9th - MarketBeat
Best Nanotechnology Stocks To Follow Today – May 31st - Defense World
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading 4.4% Higher – Still a Buy? - Defense World
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
Promising Nanotechnology Stocks To Watch Now – May 7th - The AM Reporter
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Up 5.5% – Here’s What Happened - Defense World
Virpax(R) Pharmaceuticals Announces Appointment of Michèle C. Linde, EVP, General Counsel - ACCESS Newswire
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Increase in Short Interest - Defense World
VRPX stock plunges to 52-week low, touches $1.07 - Investing.com Australia
Virpax Pharmaceuticals Faces Nasdaq Delisting Notice and Leadership Changes - TipRanks
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split By Investing.com - Investing.com UK
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com
Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com
Breakthrough: Virpax's 5-Day Pain Drug Passes Critical Safety Test - Stock Titan
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET - MyChesCo
Could This Needle-Free COVID Vaccine Technology Transform Vaccine Delivery? - Stock Titan
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS - Business Wire
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Virpax lauds Nanomerics’ MET study with no severe side effects - Investing.com India
Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - Stock Titan
VRPX stock touches 52-week low at $0.23 amid market challenges - Investing.com
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Yahoo Finance
Military Breakthrough: New Pain Control Drug Shows 96-Hour Combat Effectiveness in Army Tests - Stock Titan
Virpax Pharmaceuticals director resigns due to compliance - Investing.com
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference - Business Wire
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering - GlobeNewswire
Virpax Pharmaceuticals sets public offering at $0.20 per share - Investing.com
Virpax Pharmaceuticals enacts reverse stock split - Investing.com
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Virpax Pharmaceuticals Inc Stock (VRPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.06%
0.60%
Cap:
|
Volume (24h):